As of May 23, 2025, Eli Lilly and Co (LLY) reports a Net Margin of 23.51%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Eli Lilly and Co's Net Margin
Over recent years, Eli Lilly and Co's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 23.51% |
| 2023-12-31 | 15.36% |
| 2022-12-31 | 21.88% |
| 2021-12-31 | 19.71% |
| 2020-12-31 | 25.24% |
This slight upward trend highlights how Eli Lilly and Co manages its overall profitability and cost control over time.
Comparing Eli Lilly and Co's Net Margin to Peers
To better understand Eli Lilly and Co's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Eli Lilly and Co (LLY) | 23.51% |
| Cronos Group Inc (CRON.TO) | 34.93% |
| Zoetis Inc (ZTS) | 26.86% |
| Merck & Co Inc (MRK) | 26.68% |
| Corcept Therapeutics Inc (CORT) | 20.92% |
| Horizon Therapeutics PLC (HZNP) | 14.37% |
Compared to its competitors, Eli Lilly and Co's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.